Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 44 (3), 519-35

Practical Aspects in Choosing a Helicobacter Pylori Therapy

Affiliations
Review

Practical Aspects in Choosing a Helicobacter Pylori Therapy

Javier Molina-Infante et al. Gastroenterol Clin North Am.

Abstract

Cure rates greater than 90%-95% should be expected with an antimicrobial therapy for Helicobacter pylori infection. Standard triple therapy does not guarantee these efficacy rates in most settings worldwide anymore. The choice of eradication regimen should be dictated by factors that can predict the outcome: (1) H. pylori susceptibility; (2) patients' history of prior antibiotic therapy; and (3) local data, either resistance patterns or clinical success. Currently, the preferred first-line choices are 14-day bismuth quadruple and 14-day non-bismuth quadruple concomitant therapy. Bismuth quadruple (if not used previously), fluoroquinolone-, furazolidone- and rifabutin-containing regimens might be effective rescue treatments.

Keywords: Bismuth; Concomitant; Eradication; Helicobacter pylori; Quadruple; Resistance; Therapy; Triple.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

MeSH terms

Feedback